Christopher Peetz has bought MIRM on 2 days since Sep 2019

Chris Peetz is the Chief Executive Officer and co-founder of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on developing and commercializing therapies for rare liver diseases.( He has led Mirum since its founding in May 2018, guiding the company through its IPO in July 2019 and key milestones such as the approval of Livmarli for Alagille syndrome, acquisitions like Bluejay Therapeutics and Travere Therapeutics’ bile acid portfolio, and achieving cash-flow positivity.(

Peetz's career spans executive roles in biotech, including CEO of Flashlight Therapeutics, CFO and head of corporate development at Tobira (acquired by Allergan), VP of finance and corporate development at Jennerex Biotherapeutics, and various positions at Onyx Pharmaceuticals (now Amgen).( An entrepreneur-in-residence at Frazier Healthcare Partners since 2017, he also serves on the board of Alpine Immune Sciences.( He holds an M.B.A. from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business, and French from Washington University in St. Louis.( Recently, as a corporate insider, he sold shares worth $941k on February 2, 2026, to cover tax obligations, retaining significant holdings.(

Written by Perplexity from public sources.